Foresite Capital Management Iii, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Foresite Capital Management Iii, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$29.01 - $74.23 $1.81 Million - $4.62 Million	-62,245 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$27.51 - $57.29 $1.71 Million - $3.57 Million	62,245 New	62,245 $2.12 Million
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $2.18 Million - $3.08 Million	-53,345 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$37.38 - $49.47 $444,971 - $588,890	-11,904 Reduced 18.24%	53,345 $2.23 Million
Q2 2019 Aug 13, 2019	SELL	$39.79 - $67.01 $442,862 - $745,821	-11,130 Reduced 14.57%	65,249 $2.86 Million
Q1 2019 May 14, 2019	SELL	$34.52 - $53.29 $1.01 Million - $1.56 Million	-29,327 Reduced 27.74%	76,379 $3.93 Million
Q4 2017 Feb 13, 2018	BUY	$20.44 - $35.56 $2.16 Million - $3.76 Million	105,706 New	105,706 $2.85 Million
Q3 2017 Nov 13, 2017	SELL	$23.54 - $38.21 $706,200 - $1.15 Million	-30,000 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	30,000	30,000 $750,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.